Obezitede Endoskopik Tedavi Yöntemleri

States U, Flegal KM. Prevalence of Obesity Among Adults and Youth . 2015; (219):2011-2014.

TÜİK (2014). Türkiye Sağlık Araştırması, 2019. 12/01/2021 tarihinde https://tuikweb.tuik.gov.tr/PreHaberBultenleri.do?id=33661 adresinden ulaşılmıştır).

Eric JV, Monika R, Fateh B. Medical Devices for Obesity Treatment: Endoscopic Bariatric Therapies. Med Clin N Am. 2018;102:149-163.

Topazian M, Camilleri M, Enders FT, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013; 11(2):145–50.

Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989; 35:381-5.

Behary J, Kumbhari V. Advances in the endoscopic management of obesity. Gastroenterol. Res. Pract. 2015;2015:757821.

Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008; 8:841-6.

Yorke E, Switzer NJ, Reso A, et al. Intragastric balloon for management of severe obesity: a systematic review. Obes Surg. 2016; 26:2248-54.

Sullivan S, Swain JM, Woodman G, et al. The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. Gastroenterology. 2016; 150:S1267.

Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011; (10):1499–507.

James AN, Ryan JP, Parkman HP, et al. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol.2003; 285:G291–G297.

García-Compean D, Maldonado Garza H. Intragastric injection of botulinum toxin for the treatment of obesity.Where are we? World J Gastroenterol. 2008;14:1805–9.

Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23(5):675–80.

Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015; 82(3): 425–38.e5.

Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015; 29(11):3298–303.

Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016; 39(12): 2254–61.

Machytka E, Buzga M, Lautz DB, et al. 103 a dual-path enteral bypass procedure created by a novel incisionless anastomosis system (IAS): 6-month clinical results. Gastroenterology. 2016; 150(4):S26

Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017; 27(10):2649–55.

Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013;145:1245-52.

Espinos JC, Turro R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the pose procedure. Obes Surg. 2016;26(5):1081–9.